SpringWorks Therapeutics, Inc. (SWTX)

Market Cap	2.86B
Revenue (ttm)	135.49M
Net Income (ttm)	-275.16M
Shares Out	74.37M
EPS (ttm)	-3.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,338,482
Open	35.95
Previous Close	35.82
Day's Range	35.95 - 40.12
52-Week Range	28.21 - 53.92
Beta	0.81
Analysts	Strong Buy
Price Target	68.83 (+79.25%)
Earnings Date	Feb 20, 2025

About SWTX

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer....

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 13, 2019
• Employees: 305
• Stock Exchange: NASDAQ
• Ticker Symbol: SWTX
• Website: https://www.springworkstx.com

Analyst Forecast

According to 6 analysts, the average rating for SWTX stock is "Strong Buy." The 12-month stock price forecast is $68.83, which is an increase of 79.25% from the latest price.

Price Target

$68.83

(79.25% upside)

Analyst Consensus: Strong Buy